Taken together, our study demonstrated that NEDD4 could be an ideal therapeutic target for GC patients with abnormal activation of the IGF1/IGF1R pathway, and simultaneous targeting of IGF1R and NEDD4 may be an effective treatment for these patients. Here, IGF1 is linked to gastric cancer.